Company news
Allogene Therapeutics, Inc. news in 2021
Allogene Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
December 14, 2021
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
December 12, 2021
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
November 30, 2021
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
November 11, 2021
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
November 3, 2021
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
October 27, 2021
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
October 6, 2021
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
August 31, 2021
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
August 11, 2021
Allogene Therapeutics Reports Second Quarter 2021 Financial Results
August 3, 2021
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
August 1, 2021
Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
June 29, 2021
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
June 20, 2021
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
June 3, 2021
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
May 11, 2021
Allogene Therapeutics Reports First Quarter 2021 Financial Results
May 4, 2021
Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
April 26, 2021
Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
April 20, 2021
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
April 18, 2021
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
April 11, 2021
Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
April 9, 2021
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
February 24, 2021
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
January 25, 2021
Calls in 2021
- Allogene Therapeutics (NASDAQ:ALLO) Q3 2021 Earnings Call
Nov 4, 2021
Transcript - Allogene Therapeutics (NASDAQ:ALLO) Q2 2021 Earnings Call
Aug 4, 2021
Transcript - Allogene Therapeutics (NASDAQ:ALLO) Q1 2021 Earnings Call
May 5, 2021
Transcript - Allogene Therapeutics (NASDAQ:ALLO) Q4 2020 Earnings Call
Feb 25, 2021
Transcript